J. T. Fine

TL;DR: The VIVA (Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis) trial as discussed by the authors was designed to evaluate the safety and efficacy of intracoronary and intravenous infusions of rhVEGF.

TL;DR: These results suggest a greater burden of DME among non-Hispanic blacks, individuals with high levels of hemoglobin A1c, and those with longer duration of diabetes.

TL;DR: Treatment of neovascular AMD with ranibizumab can improve patient-reported visual function in a meaningful way compared with sham treatments, and in MARINA, ranibIZumab-treated patients were more likely to report visual function improvements at 12 and 24 months.

TL;DR: Analysis of patient perception of vision-related function in phase III trials evaluating ranibizumab for neovascular AMD demonstrates improved patient-reported outcomes regardless of whether the treated eye is the better- or worse-seeing eye at onset of treatment, and supports treatment of such lesions with ranibzumab, even those in the worse-Seeing eye.

TL;DR: At each dose through 24 months, patients treated with ranibizumab were more likely to improve in most subscales, including the prespecified subscales (near activities, distance activities, and vision-specific dependency).